- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06615505
ASCEND: 퇴행성 추간판용 보충제인 VIA Disc NP의 안전성과 유효성을 평가하기 위한 무작위, 이중 맹검, 가짜 대조, 다기관 1상/2상 임상 시험 (ASCEND)
ASCEND: A Randomized, Double Blind, Sham-Controlled, Multi-Center Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs
VIA Disc NP is an off-the-shelf minimally processed human nucleus pulposus tissue allograft intended to supplement degenerated intervertebral discs.
The study is a randomized, double-blind, sham-controlled, multi-center study in participants with symptomatic lumbar intervertebral disc degeneration (> 6 months) and unresponsive to conservative therapy for at least 3 months. Participants will be randomized on a 1:1 basis to receive either a single VIA Disc NP intradiscal injection at 1 or 2 levels or a sham procedure at 1 or 2 levels.
Participants who consent to participate in the study and meet all eligibility criteria during the Screening/Baseline period will return on Day 1 to be randomized to either the VIA Disc NP or sham-control group. At 12-weeks post-treatment, participants allocated to the sham-control group will be given the option to crossover to the VIA Disc NP group if they meet the requirement to crossover.
All participants will be followed through 52-weeks post-treatment at which time they will be asked if they would like to consent to participate in an extended long-term follow-up period. The sham-control group participants who did not crossover at 12-weeks will be exited from the study at this visit. If participants consent to participate in the extended long-term follow-up period, the VIA Disc NP group will be followed through 24-Months and the sham-control group will be followed through 27-months. If the participant declines participation, they will be exited from the study at this visit.
연구 개요
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
New South Wales
-
Broadmeadow, New South Wales, 호주, 2292
- Genesis Research Services Pty Ltd
-
Hurstville, New South Wales, 호주, 2220
- Australian Medical Research
-
Wahroonga, New South Wales, 호주, 2076
- Sydney Pain Research Centre
-
-
South Australia
-
Wayville, South Australia, 호주, 5034
- Cercare Clinical Research
-
-
Victoria
-
Clayton, Victoria, 호주, 3168
- Monash House Research Centre Pty Ltd
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Age 22 to 85 years old
- Diagnosis of early to moderate DDD, Modified Pfirrmann Grade 3-7
- Chronic axial midline low-back pain with or without referred non-radicular leg pain for at least 6 months prior to screening; unresponsive to at least 3 months of conservative care
- Positive hip flexion test as confirmed with the Neurologic Exam indicating positive provocation with sustained hip flexion at the time of screening
- Demonstrated intolerance to sitting for more than 30 minutes at a time based on self-report or assessed by a qualified healthcare professional at the screening visit
- Low-back pain severity score of ≥ 40 to ≤ 90 mm on the VAS at the time of Screening
- ODI score of ≥ 40 to ≤ 80 at the time of Screening
Key Exclusion Criteria:
-
Contraindication to MRI for any reason
-
Contraindications to the proposed sedation/anesthetic protocol
-
Symptomatic involvement of more than two lumbar discs
-
Fracture of the lumbar spine, previous lumbar spine surgery or previous treatment of the target disc(s)
-
Grade 2 or higher spondylolisthesis at the target disc, lumbar spondylitis or other undifferentiated spondyloarthropathy, or Type III Modic changes around the target disc
-
Clinical suspicion of a full thickness annular tear at the target disc or other abnormal disc morphology
-
Clinical suspicion of facet pain as primary pain generator
-
Women who are pregnant or breastfeeding at the time of enrollment and/or plan to become pregnant during the study. Pregnancy is confirmed by:
- A positive pregnancy test during the screening visit
- Self-reported pregnancy
-
Women of childbearing potential (WOCBP) who are not using a reliable form of contraception (as determined by the Investigator)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
가짜 비교기: 샴 암
|
Participants will receive the sham procedure at 1 or 2 levels. The procedure will be identical to the investigational procedure with the following exception: A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc. |
|
활성 비교기: VIA 디스크 NP
|
Participants will receive a single dose, intradiscal injection of 100 mg of VIA Disc NP mixed with sterile saline according to product Instructions for Use (IFU) and administered to the affected level(s), L1-S1 (1 or 2 levels). |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Primary Effectiveness Endpoint - Proportion of participants achieving MCID in VAS score from Baseline to 26 weeks.
기간: Baseline to 26 Weeks
|
A comparison of the proportion of participants who show a minimally clinically important difference (MCID), defined as at least a 30% reduction in back pain VAS score from baseline to 26 weeks (6 months), in the VIA Disc NP group to that in the sham-control group. |
Baseline to 26 Weeks
|
|
Primary Safety Endpoint - Proportion of participants reporting Treatment-related AEs at 12 weeks
기간: Baseline to 12 weeks
|
The proportion of participants that experience one or more treatment-related (including procedure) adverse events in the VIA Disc NP group compared to the sham-control group at 12 weeks (3 months) as determined by the Principal Investigator. |
Baseline to 12 weeks
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- VIA-2024-001
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .